Head-to-head clinical analysis & difference comparison: details on mechanism of action, dosing, half-life, interactions, and maternal-fetal safety.
NITROSTAT vs ISMO
Clinician-reviewed, head-to-head comparison of mechanism, dosing, pharmacokinetics, and safety profiles.
Last clinically reviewed: July 2026 · OpiCalc Medical Review Team
Nitroglycerin is a prodrug that releases nitric oxide (NO), which activates guanylyl cyclase, increasing c GMP in vascular smooth muscle, leading to vasodilation. Preferentially dilates coronary arteries and veins, reducing preload and afterload.
Isosorbide mononitrate is a nitrate that dilates coronary arteries and peripheral veins. It acts by releasing nitric oxide, which activates guanylate cyclase, increasing c GMP levels, leading to smooth muscle relaxation and vasodilation.
Acute relief of angina pectoris,Prophylaxis of angina pectoris before activities that may provoke an attack,Off-label: Treatment of acute heart failure, hypertensive urgency
Prevention of angina pectoris due to coronary artery disease,Off-label: Treatment of acute angina (immediate-release forms)
0.3-0.6 mg sublingually or buccally every 5 minutes as needed for angina relief, up to a maximum of 3 doses in 15 minutes.
20 mg orally twice daily, 7 hours apart (e.g., 8 AM and 3 PM) to minimize nitrate tolerance.
2–3 minutes for initial distribution phase; terminal elimination half-life is approximately 1–4 minutes. Rapid clearance due to extensive metabolism in the liver and other tissues (via glutathione-organic nitrate reductase).
Terminal elimination half-life is approximately 5-6 hours. In elderly patients or those with hepatic impairment, half-life may be prolonged (up to 8-10 hours), warranting dose adjustment.
Rapidly metabolized in the liver by glutathione-organic nitrate reductase and by erythrocytes; CYP450 not primarily involved.
Primarily metabolized in the liver by denitration; minor metabolism via glucuronidation. Metabolites are inactive.
Renal excretion of inactive metabolites accounts for approximately 60% of elimination; biliary/fecal excretion accounts for about 35%. Unchanged nitroglycerin is minimally excreted in urine (<1%).
Primarily renal; 80-90% of the dose is excreted as inactive metabolites (isosorbide mononitrate and isosorbide dinitrate) in urine. Less than 1% is excreted unchanged. Fecal excretion is minimal.
Approximately 60% bound to plasma proteins (albumin and possibly others).
Approximately 30% bound to plasma proteins, primarily albumin.
3–4 L/kg, indicating extensive distribution into tissues, particularly vascular smooth muscle and other highly perfused organs.
Vd is 0.6-0.9 L/kg, indicating distribution into total body water. Higher Vd may be observed in patients with heart failure.
Sublingual: 30–60% (bypasses first-pass hepatic metabolism). Oral: <10% due to extensive first-pass metabolism. Transdermal: 10–20% depending on formulation and application site. Intravenous: 100%.
Oral: 90-100% (sustained-release formulations). Sublingual: high but variable; generally effective due to extensive absorption.
No dosage adjustment required for renal impairment; use with caution in patients with severe renal impairment due to potential for hypotension.
No dose adjustment required for GFR ≥30 m L/min. For GFR <30 m L/min, consider reducing dose to 10 mg twice daily due to potential accumulation of active metabolite.
Child-Pugh Class A: No adjustment; Child-Pugh Class B: Caution, consider dose reduction; Child-Pugh Class C: Avoid use due to increased risk of methemoglobinemia.
No dose adjustment in Child-Pugh A or B. For Child-Pugh C, reduce dose to 10 mg twice daily and monitor for hypotension.
Not recommended for use in children due to lack of safety and efficacy data.
Safety and efficacy not established; no standard dosing recommendations.
Initiate at lower end of dosing range (0.3 mg) due to increased sensitivity to vasodilation and higher risk of hypotension; monitor closely.
Start at 10 mg twice daily with gradual titration based on tolerance and renal function. Monitor for hypotension and dizziness.
Do not use with phosphodiesterase-5 inhibitors (e.g., sildenafil, tadalafil) as this can cause severe hypotension, syncope, or myocardial ischemia.
Do not use with phosphodiesterase-5 (PDE-5) inhibitors (e.g., sildenafil, tadalafil) due to risk of severe hypotension.
Hypotension and reflex tachycardia may occur,May exacerbate angina due to excessive hypotension,Tolerance may develop with prolonged use,Abrupt discontinuation may precipitate angina
Hypotension and reflex tachycardia may occur,Caution in patients with volume depletion or hypotension,May cause headaches; tolerance may develop with prolonged use,Abrupt withdrawal may increase angina frequency
Hypersensitivity to nitroglycerin,Concurrent use of phosphodiesterase-5 inhibitors (sildenafil, tadalafil, vardenafil),Severe hypotension (systolic BP <90 mm Hg),Cardiac tamponade, constrictive pericarditis, or restrictive cardiomyopathy,Increased intracranial pressure (e.g., head trauma, cerebral hemorrhage)
Concurrent use of PDE-5 inhibitors,Severe anemia,Closed-angle glaucoma,Hypersensitivity to isosorbide mononitrate or nitrates,Acute myocardial infarction with low filling pressures
Avoid alcohol, which can enhance hypotensive effects and cause severe dizziness or fainting. Grapefruit juice may increase nitroglycerin absorption and risk of adverse effects. No other significant food interactions.
Alcohol may enhance hypotension risk. Avoid high-fat meals if extended-release formulation, as they may affect absorption. No other significant food interactions.
FDA Pregnancy Category C. Nitroglycerin crosses the placenta. Animal studies show no teratogenic effects. Use in first trimester only if clearly needed; second/third trimester: risk of fetal bradycardia and hypotension. Avoid near term due to potential for maternal hypotension and reduced uterine blood flow.
ISMO (isosorbide mononitrate) is categorized as FDA Pregnancy Category C. In animal studies, reduced fetal survival and growth retardation were observed at high doses. No adequate human studies exist. Use only if potential benefit justifies risk. First trimester: Theoretical risk of hemodynamic effects; avoid unless necessary. Second/third trimester: May cause fetal hypoxia due to maternal hypotension; monitor fetal heart rate. Peripartum: May exacerbate uterine relaxation and postpartum hemorrhage if used near delivery.
Nitroglycerin is excreted into breast milk in small amounts; M/P ratio unknown. No known adverse effects in infants. Use with caution, especially in nursing of premature or ill infants.
Excretion into human milk is unknown. Due to risk of infant methemoglobinemia and hypotension, caution is advised. M/P ratio: Not available. American Academy of Pediatrics considers nitrate derivatives compatible with breastfeeding, but monitor infant for cyanosis and lethargy.
No specific dose adjustment required for pregnancy; however, due to increased plasma volume and altered hemodynamics, monitor efficacy and titrate to response. Use lowest effective dose to minimize maternal hypotension.
No specific dose adjustments for ISMO in pregnancy are established due to lack of pharmacokinetic studies. However, pregnancy-induced hemodynamic changes (increased plasma volume, cardiac output) may reduce efficacy; consider dose titration based on clinical response. Avoid doses >60 mg/day to minimize hypotensive risk. Use immediate-release formulations for flexible dosing if needed.
Nitroglycerin sublingual tablets (Nitrostat) are first-line for acute angina. Store in original glass bottle, tightly closed; potency degrades with exposure to light, heat, and moisture. Patients should feel a tingling or burning sensation under the tongue—if absent, tablet may be ineffective. Administer 0.3-0.6 mg at first sign of angina; may repeat every 5 minutes up to 3 doses. If pain persists after 3 doses, seek emergency care. Contraindicated with recent use of PDE-5 inhibitors (sildenafil, tadalafil, vardenafil) due to severe hypotension. Hypotension and reflex tachycardia are common; monitor blood pressure. Tolerance develops with sustained use; use minimal effective dose and allow nitrate-free interval (10-12 hours daily) for long-acting forms.
ISMO (isosorbide mononitrate) is a nitrate used for angina prophylaxis, not for acute attacks. Tolerance develops with sustained use; maintain a 10-12 hour nitrate-free interval to prevent tolerance. Do not use with phosphodiesterase-5 inhibitors (e.g., sildenafil) due to risk of profound hypotension. Contraindicated in severe anemia, increased intracranial pressure, or hypertrophic obstructive cardiomyopathy. Discontinue if blurred vision or dry mouth occurs.
Take at the first sign of chest pain; do not wait for severe pain.,Place the tablet under the tongue or between the cheek and gum; do not swallow or chew.,Sit or lie down when taking to avoid dizziness or fainting from low blood pressure.,If no relief after 5 minutes, repeat one dose; if still no relief after 3 doses in 15 minutes, call 911 immediately.,Store in the original glass bottle, tightly closed, away from heat and light; do not store in bathroom or kitchen.,Replace the bottle 6 months after opening, as the medication loses potency.,Do not drink alcohol while taking this medication; it can cause severe hypotension.,Do not take with erectile dysfunction drugs (Viagra, Cialis, Levitra) as it can cause a fatal drop in blood pressure.,Avoid grapefruit juice as it may increase side effects.
Take as prescribed to prevent angina; do not use for acute attacks.,May cause headache, dizziness, or hypotension; rise slowly from sitting.,Avoid taking erectile dysfunction drugs (e.g., sildenafil, tadalafil) as severe blood pressure drop can occur.,Do not stop abruptly to avoid rebound angina.,Store in original container away from light and moisture.
No interactions on record
"Bosentan, a dual endothelin receptor antagonist and an inducer of CYP3A4 and CYP2C9, reduces systemic exposure to vismodegib, a Hedgehog pathway inhibitor primarily metabolized by CYP3A4. This interaction leads to decreased serum concentrations of vismodegib, potentially diminishing its antitumor efficacy in patients with advanced basal cell carcinoma. Concomitant use may require vismodegib dose adjustment or alternative therapies to avoid therapeutic failure."
"Vismodegib inhibits CYP3A4, which is the primary enzyme responsible for metabolizing nilotinib. Concomitant administration may lead to increased nilotinib plasma concentrations, elevating the risk of QT interval prolongation, torsades de pointes, hepatotoxicity, and myelosuppression. Clinical vigilance is warranted due to the narrow therapeutic index of nilotinib."
"Vismodegib, a hedgehog pathway inhibitor, is a moderate inhibitor of CYP2C9, the primary enzyme responsible for metabolizing tolbutamide. Concomitant use can significantly decrease tolbutamide clearance, leading to elevated plasma concentrations and prolonged hypoglycemic effects. This increases the risk of severe hypoglycemia, especially in diabetic patients, and may require dose adjustment of tolbutamide."
Explore head-to-head clinical comparisons of other medications in the same therapeutic classes.
Common clinical questions about NITROSTAT vs ISMO, answered by our medical review team.
NITROSTAT is a Nitrate Vasodilator that works by Nitroglycerin is a prodrug that releases nitric oxide (NO), which activates guanylyl cyclase, increasing c GMP in vascular smooth muscle, leading to vasodilation. Preferentially dilates coronary arteries and veins, reducing preload and afterload.. ISMO is a Nitrate Vasodilator that works by Isosorbide mononitrate is a nitrate that dilates coronary arteries and peripheral veins. It acts by releasing nitric oxide, which activates guanylate cyclase, increasing c GMP levels, leading to smooth muscle relaxation and vasodilation.. They differ in pharmacokinetic profiles, FDA-approved indications, and side effect profiles.
Potency comparisons between NITROSTAT and ISMO depend on the specific clinical indication. These are both Nitrate Vasodilator agents and are not directly interchangeable by dose. A physician or clinical pharmacist should guide any therapeutic switching decisions.
The standard adult dose of NITROSTAT is: 0.3-0.6 mg sublingually or buccally every 5 minutes as needed for angina relief, up to a maximum of 3 doses in 15 minutes.. The standard adult dose of ISMO is: 20 mg orally twice daily, 7 hours apart (e.g., 8 AM and 3 PM) to minimize nitrate tolerance.. Dosing should always be individualized based on indication, renal and hepatic function, age, and other patient factors.
No direct drug-drug interaction has been formally documented between NITROSTAT and ISMO in current clinical databases. However, individual patient risk factors including other medications, organ function, and comorbidities should always be evaluated by a qualified healthcare provider.
The maternal-fetal safety profiles differ. NITROSTAT is classified as Category C. FDA Pregnancy Category C. Nitroglycerin crosses the placenta. Animal studies show no teratogenic effects. Use in first trimester only if clearly needed; second/third trimester: ris. ISMO is classified as Category C. ISMO (isosorbide mononitrate) is categorized as FDA Pregnancy Category C. In animal studies, reduced fetal survival and growth retardation were observed at high doses. No adequate . Always consult a maternal-fetal medicine specialist before taking either drug during pregnancy or lactation.